Durvalumab Combo Improves Clinical Benefits Vs Chemo in Metastatic NSCLC
September 16th 2023Baseline characteristics do not appear to correlate with long-term benefits for patients receiving durvalumab plus tremelimumab and chemotherapy for metastatic non–small cell lung cancer in the phase 3 POSEIDON trial.
Hossein Borghaei, DO, MS, Discusses the Future of Biomarker Research for Immunotherapy in NSCLC
August 27th 2022In an interview with CancerNetwork®, Hossein Borghaei, DO, MS, details the promising body of ongoing research assessing biomarkers in patients with non–small cell lung cancer who are candidates for treatment with immunotherapy.
Impressive Responses Observed With Ociperlimab Plus Tislelizumab in Treatment-Naïve, PD-L1+ NSCLC
August 14th 2022Ociperlimab plus tislelizumab showed promising antitumor activity in patients with treatment-naïve, metastatic, PD-L1–positive non–small cell lung cancer who were treated on the phase 1 AdvanTig-105 trial.
Tislelizumab Maintains OS Benefit vs Docetaxel in Previously Treated NSCLC
August 13th 2022Results from the phase 3 RATIONALE-303 trial presented at 2022 WCLC showed an overall survival benefit when patients with non–small cell lung cancer were treated with second- or third-line tislelizumab compared with docetaxel.
Efficacy, Safety With Datopotamab Deruxtecan Plus Pembrolizumab Regimen Observed in Advanced NSCLC
August 9th 2022TROPION-Lung02 trial provides evidence of datopotamab deruxtecan and pembrolizumab efficacy in patients with advanced/metastatic non–small cell lung cancer and no actionable genomic alterations.
Talazoparib Plus Low-Dose Temozolomide Bests Historical Controls in R/R ES-SCLC
August 8th 2022Data from the phase 2 UCLA/TRIO-US L-07 trial presented at 2022 WCLC revealed that efficacy with talazoparib plus temozolomide improves upon historical controls in patients with extensive-stage small cell lung cancer.
Neoadjuvant Nivolumab/Chemo Demonstrates Superiority Vs Chemo Alone in Resectable Stage IIIA/B NSCLC
August 8th 2022Data from the phase 2 NADIM II trial appear to reinforce the superiority of nivolumab and chemotherapy vs chemotherapy alone after the regimen significantly improved overall survival progression-free survival, and pathologic complete response in patients with stage IIIA/B non–small cell lung cancer, according to investigators.